 Ipsen exclusively licensed its European rights to Menarini in 2009.Teijin partnered with Astellas for distribution in China and southeast Asia.In the UK, NICE has found that febuxostat has a higher cost/benefit ratio than allopurinol and on that basis recommended febuxostat as a second-line drug for people who cannot use allopurinol.